Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD30.CAR-T in Relapsed or Refractory CD30+ Non-Hodgkin Lymphoma
NCT04526834Phase 1Active, not recruiting
- Sponsor
- Tessa Therapeutics
- Start
- Sep 2021
- Primary completion
- Nov 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous CD30.CAR-T in anaplastic large cell lymphoma (ALCL), peripheral T-cell lymphoma (PTCL), Extranodal NK/T-cell lymphoma (ENKTL) and 2 more, sponsored by Tessa Therapeutics. Primary endpoint: Dose Limiting Toxicity. Started Sep 2021; status: active, not recruiting.
02
Drugs
autologous CD30.CAR-T
03
Conditions
anaplastic large cell lymphoma (ALCL)peripheral T-cell lymphoma (PTCL)Extranodal NK/T-cell lymphoma (ENKTL)diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT04526834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04526834.